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 Abstract 
 Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-
acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its 
pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been 
documented. The aim of this study was to analyze and compare the effects of carvedilol and 
metoprolol on the development of CIN in patients undergoing coronary angiography.  Meth-
ods: One hundred patients currently taking metoprolol and 100 patients currently taking 
carvedilol were enrolled into the study. Venous blood samples were obtained before and
48 h after contrast administration. Cystatin C and malondialdehyde values were examined 
and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from 
the baseline value.  Results: Seven patients in the carvedilol group (7%) and 22 patients in 
the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median 
cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h af-
ter radiocontrast administration. In the carvedilol group, the median cystatin C concentration 
did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the 
mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 
nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration 
did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59).  Conclusion: When 
compared to metoprolol, carvedilol might decrease oxidative stress and subsequent devel-
opment of CIN.  © 2015 S. Karger AG, Basel 
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 Introduction 
 Hypoxic injury to the renal medulla plays a major part in the pathogenesis of contrast-
induced nephropathy (CIN)  [1] . However, factors other than hypoxic medullary injury may 
be involved in CIN pathogenesis. They include tubular obstruction by radiocontrast media, 
precipitated crystals of oxalate or uric acid  [2] and direct tubular toxicity possibly involving 
the generation of oxygen free radicals and lipid peroxidation  [2–4] . These processes may 
coexist and act in concert with hypoxic medullary injury  [1] . Several interventions and drugs 
have been advocated to reduce contrast-associated morbidity and mortality, but very few 
have consistently shown benefit  [5] . Periprocedural hydration and the use of small amounts 
of low-osmolality contrast agents have been considered to be the first-line measures for CIN 
prevention. 
 Carvedilol is a third-generation nonselective β-blocker with the features of a β- and 
α-receptor blocker. It also has antioxidant and vasodilator effects  [6–8] . In this study, we 
sought to examine the efficacy of carvedilol when compared to metoprolol, an old-generation 
β-blocker, without any proven antioxidant effect, for the prevention of CIN in patients under-
going coronary angiography.
 Methods 
 All consecutive patients admitted to Baskent University Ankara Hospital on an outpatient basis between 
December 2009 and August 2010 were evaluated for possible enrollment into the study. The study was 
conducted in accordance with the guidelines proposed in the Declaration of Helsinki and was approved by 
the local ethics committee. Each patient provided a signed informed consent form.
 The following patients were excluded from the study: patients with known malignancy, liver disease, 
active infection or allergy to contrast media, patients using vitamins or other known antioxidant agents, 
patients who had used any nephrotoxic agent in the previous 48 h or who had had exposure to a contrast 
agent in the previous 7 days, patients with unstable angina, hemodynamically unstable patients or patients 
who required immediate percutaneous coronary intervention.
 All patients had been taking a sustained dose, determined by the following physician, of carvedilol or 
metoprolol for at least 1 month before possible enrollment into the study. The doses of the drugs were not 
changed during the study period. The study design is summarized in  figure 1 . 
 In order to evaluate each patient’s kidney functions, serum creatinine and cystatin C levels were 
evaluated using venous blood samples before and 48 h after contrast administration. Similarly, to 
evaluate oxidative status, malondialdehyde levels were analyzed from venous blood samples before and 
48 h after coronary angiography. Glomerular filtration rate was estimated using the Cockcroft-Gault 
formula. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl at 48 h of contrast exposure. 
A nonionic low-osmolar contrast agent (iohexol) was used in all patients. The amount of contrast sub-
stance used was recorded for each patient. Saline infusion with a rate of 1 ml/kg/h was given for 12 h 
before contrast exposure; after contrast exposure, saline infusion with a rate of 1 ml/kg/h was continued 
for 24 h.
 Biochemical Analysis 
 Serum creatinine was assayed using the kinetic Jaffe method, rate-blanked and compensated using a 
Hitachi Modular PP Analyzer (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufac-
turer’s specifications. Serum cystatin C was measured by enzyme-linked immunosorbent assay (ELISA) using 
96-well microplates (BioVendor Laboratory Medicine, Inc., CTPark Modrice, Modrice, Czech Republic) 
according to the manufacturer’s instructions of the DYNEX Technologies DSX Modal Microelisa Analyzer. The 
detection limit was 0.2 ng/ml. The intra- and interassay variabilities were 9.6 and 6.2%, respectively. Serum 
malondialdehyde levels were determined using the spectrophotometric method at 532 nm after boiling the 
sample and condensing it with thiobarbituric acid  [9] .
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 Statistical Analysis 
 Continuous variables are presented as means ± SD if normally distributed or as medians with ranges. 
Normality was tested using the Shapiro-Wilk test. Categorical variables are presented as numbers and 
percentages and were compared using the Fisher exact test. For comparison of the continuous variables, the 
t tests, the Mann-Whitney U test or the Wilcoxon signed-rank test were used, whichever was appropriate. A 
p value of <0.05 was considered statistically significant. The SPSS for Windows version 11.5 statistical 
software (SPSS Inc., Chicago, Ill., USA) was used for all the statistical calculations.
Patients who received an effective dose, determined by the following physician, of metoprolol
or carvedilol for at least 1 month before angiography were evaluated 
757 patients using either carvedilol or metoprolol were admitted to the cardiology outpatient
clinic between December 2009 and August 2010
Patients with noncardiac chest pain were excluded
123 patients in the carvedilol group 118 patients in the metoprolol group
Excluded
  2 patients unwilling to join the study
  3 patients with missing data
  4 patients who changed medications
     Total included: 100 patients
14 patients who underwent 
     percutaneous coronary intervention
Excluded
  1 patient unwilling to join the study
  4 patients with missing data
  2 patients who changed medications
     Total included: 100 patients
11 patients who underwent 
     percutaneous coronary intervention
200 patients
Creatinine, malondialdehyde and cystatin C before and 48 h after
coronary angiography
 Fig. 1. Study design. 
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 Results 
 Two hundred patients were evaluated prospectively. There were no significant differ-
ences in baseline clinical characteristics between the carvedilol and metoprolol groups 
( table 1 ). The average doses of carvedilol and metoprolol were 25 (range 12.5–50) and 67.5 
(range 50–200) mg, respectively.
 The mean serum creatinine concentration for all patients was 0.87 ± 0.24 (range 
0.4–1.9) mg/dl. In the metoprolol group, the mean serum creatinine concentration in-
creased significantly from 0.89 ± 0.23 to 0.96 ± 0.28 mg/dl (p = 0.007) 48 h after radiocon-
trast administration. In the carvedilol group, the mean serum creatinine concentration did 
not change significantly (0.86 ± 0.23 vs. 0.86 ± 0.25 mg/dl; p = 0.76). In the metoprolol 
group, the median cystatin C concentration increased significantly from 978 (range 
145–4,004) to 1,086 (range 303–3,840) ng/ml (p = 0.001). In the carvedilol group, the 
median cystatin C concentration did not change [1,143 (range 240–3,011) vs. 1,068 (range 
262–3,640) ng/ml; p = 0.94]. In the metoprolol group, the mean malondialdehyde concen-
tration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the 
carvedilol group, the mean serum malondialdehyde concentration did not change signifi-
cantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.4). There were positive correlations between 
Characteristics Carvedilol
(n = 100)
Metoprolol
(n = 100)
p
Age, years 63 ± 9 65 ± 9 0.1
Male gender 57 62 0.4
BMI 29.13 ± 3.58 28.16 ± 3.87 0.06
Hypertension 98 98 1
Diabetes 43 44 0.8
Hyperlipidemia 75 76 0.8
Smoking 26 35 0.6
History of MI 6 3 0.49
History of PCI 30 19 0.10
History of CABG 10 14 0.52
LVEF, % 54.3 ± 10.3 54.6 ± 8.9 0.84
Medication use
ACE inhibitor 47 51 0.57
ARB 36 28 0.22
 Ca channel blocker 17 17 1
α-blocker 6 9 0.4
Statins 73 80 0.24
ASA 97 95 0.7
Clopidogrel 20 32 0.053
Spironolactone 9 4 0.152
Furosemide 6 8 0.57
Insulin 24 18 0.29
Metformin 20 25 0.39
Volume of contrast media, ml 97 ± 51 105 ± 49 0.2
Hydration before angiography, ml 1,223 ± 162 1,210 ± 155 0.4
Hydration after angiography, ml 2,518 ± 383 2,466 ± 398 0.3
 Values are means ± SD or percentages. BMI = Body mass index;
MI = myocardial infarction; PCI = percutaneous coronary intervention; 
CABG = coronary artery bypass grafting; LVEF = left-ventricular ejection 
fraction; ACE = angiotensin-converting enzyme; ARB = angiotensin 
receptor blocker; Ca = calcium; ASA = acetylsalicylic acid.
 Table 1.  Baseline characteristics 
of the study population
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change in creatinine concentration and change in malondialdehyde levels (r = 0.156; p = 
0.027;  fig. 2 ) and between change in creatinine concentration and change in cystatin C (r = 
0.183; p = 0.009;  fig. 3 ). The glomerular filtration rate was unchanged in both groups after 
contrast exposure. The laboratory parameters at baseline and 48 h after contrast exposure 
are shown in  table 2 .
 CIN occurred in 22 patients in the metoprolol group and in 7 patients in the carvedilol 
group (p = 0.003). Baseline median creatinine concentrations were not different between 
patients with CIN and patients without CIN [0.8 (0.5–1.2) vs. 0.8 (0.4–1.9) mg/dl; p = 0.29]. 
In a separate analysis, when CIN was defined only as an increase in creatinine concentration 
of at least 0.5 mg/dl, there were 9 patients with CIN. All of these 9 patients were in the meto-
prolol group (p = 0.003). The dose of metoprolol was not significantly different between 
patients who developed CIN and those without CIN (71.4 ± 25.3 vs. 66.6 ± 28.6 mg; p = 0.49). 
Similarly, the dose of carvedilol was not significantly different between patients who 
developed CIN and those without CIN (25 vs. 23.9 ± 4.7 mg; p = 0.55).
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 Fig. 2. Correlations between 
change in creatinine and change 
in malondialdehyde (r = 0156; p = 
0.027). 
 Fig. 3. Correlations between 
change in creatinine and change 
in cystatin C (r = 0.183; p = 0.009). 
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 Discussion 
 In this study, we observed that carvedilol had a protective effect against CIN when 
compared to metoprolol after coronary angiography. In addition, cystatin C, a marker of renal 
function, and malondialdehyde, an oxidative end-product, were found to be increased in 
patients using metoprolol, while they were unchanged in patients taking carvedilol.
 CIN is the third most common cause of hospital-acquired acute renal failure, and its diag-
nosis is associated with numerous diagnostic and interventional procedures in daily practice 
 [10] . Serum creatinine is the most commonly used parameter for evaluating renal function, 
but serum creatinine is affected by sex, age and muscle mass. Cystatin C is a nonglycosylated 
low-molecular-weight cysteine protease inhibitor belonging to the cystatin superfamily. Its 
structure is not affected by inflammation, dietary factors, sex, age or muscle mass  [11–13] . 
Several studies examined the role of cystatin C in predicting CIN  [14–18] . Ebru et al.  [14] 
showed that only cystatin C increase after contrast media exposure is in concordance with 
the Mehran risk scoring system for predicting the risk of CIN. Another study found that 
baseline serum cystatin C levels significantly predicted the occurrence of CIN in patients with 
moderate renal insufficiency  [15] . A study from Germany demonstrated that CIN was 
predicted by baseline cystatin C, whereas creatinine, creatinine clearance and blood urea 
nitrogen were not predictive  [16] . The best predictive capabilities were provided by the 
cystatin C/creatinine ratio. In a recent study by Cicek et al.  [17] , serum cystatin C levels were 
found to be elevated in diabetic patients who developed CIN compared to those who did not. 
In contrast, Ribichini at al.  [18] observed that variations from the serum creatinine baseline 
offered a better diagnostic accuracy for predicting CIN at an earlier stage than similar varia-
tions in cystatin C. In the present study, serum cystatin C levels were significantly increased 
in the metoprolol group compared to the carvedilol group, suggesting that less deterioration 
in renal function occurred in the carvedilol group after contrast exposure.
 Oxidative stress also results in lipid peroxidation, producing malondialdehyde as an 
advanced lipoxidation end-product  [19, 20] . Malondialdehyde levels were found to be 
increased in plasma samples and kidney tissues of patients and rats with diabetic nephropathy 
 [21] . In an experimental study by Devrim et al.  [22] , serum malondialdehyde levels increased 
and nitric oxide (NO) levels decreased in rat kidney tissues after contrast exposure. As a 
 Table 2. Serum creatinine, cystatin C and malondialdehyde levels at baseline and 48 h after contrast exposure 
and prevalence of acute reduction in renal function in the carvedilol and metoprolol groups
Variable Carvedilol group
(n = 100)
Metoprolol group
(n = 100)
p
Baseline creatinine, mg/dl 0.86 ± 0.23 0.89 ± 0.23 0.25
Post-contrast creatinine, mg/dl 0.86 ± 0.25a 0.96 ± 0.28b 0.05
Baseline cystatin C, ng/ml 1,143 (240 – 3,011) 978 (145 – 4,004) 0.1
Post-contrast cystatin C, ng/ml 1,068 (262 – 3,640)a 1,086 (303 – 3,840)b 0.26
Baseline malondialdehyde, nmol/l 7.44 ± 1.21 7.09 ± 1.48 0.07
Post-contrast malondialdehyde, nmol/l 7.56 ± 1.11a 8.38 ± 2.6b 0.001
Baseline creatinine clearance 98 ± 26 94 ± 27 0.29
Post-contrast creatinine clearance 98 ± 24a 91 ± 31a 0.32
Contrast-induced nephropathy, n 7 22 0.003
Values are means ± SD or medians with ranges in parentheses. a The p value is nonsignificant when 
compared to baseline. b The p value is <0.05 when compared to baseline.
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result, they hypothesized that an increase in oxidative substances and a decrease in vasodi-
latation were responsible for the development of renal damage. Following their study, Colbay 
et al.  [23] similarly demonstrated an increase in malondialdehyde levels in the renal tissues 
of rats exposed to contrast media. The observation in our study was that malondialdehyde 
levels were found to be increased in patients using metoprolol, while they were unchanged 
in patients taking carvedilol. This finding suggests that the antioxidant properties of carvedilol 
might be the underlying mechanism in preventing CIN. In addition, carvedilol has a vasodi-
latory effect which might also be beneficial in reducing the risk of CIN.
 Patients with coronary artery disease are frequently prescribed antiischemic medica-
tions before the catheterization procedure. Because β-blockers are the first-line agents for 
patients suspected of having stable coronary artery disease  [24] , it is important to delineate 
the effects of this group of drugs on the development of CIN. Metoprolol is still one of the most 
frequent β-blocker agents prescribed by clinicians. It does not have a vasodilatory effect like 
carvedilol and nebivolol  [25] . This β-blocker was found to be ineffective in protecting the 
kidneys from ischemic episodes in a study performed on dogs  [26] . Yet, metoprolol prevented 
lipid peroxidation in experimental adult rat hearts, although it was the least effective drug 
among the lipophilic β-blockers  [27] . Tissue studies have demonstrated that nebivolol 
increases renal blood flow and glomerular filtration rate by causing dilatation in the afferent 
and efferent arterioles and that it converts reactive oxygen products formed by the nicotin-
amide adenine dinucleotide phosphate oxidase to NO by way of endothelial constitutive NO 
synthase and increases the total antioxidant action  [28, 29] . It was previously reported that 
nebivolol was effective in preventing CIN  [30–32] . The incidence of CIN was shown to be 
statistically significantly lower in the nebivolol group when compared to the metoprolol 
group in patients undergoing coronary angiography  [30] . Akgüllü et al.  [33] support our 
results by reporting that the histopathological findings after contrast exposure were re-
markably lower in rats administered carvedilol or nebivolol when compared to a control 
group. Carvedilol and nebivolol both were able to prevent the development of nephropathy 
related to contrast media by decreasing oxidative stress  [33] . In an experimental model, 
carvedilol provided protective effects against cisplatin-induced oxidative stress  [34] .
 The present study has several limitations. The subjects had already been using meto-
prolol and carvedilol at the time of recruitment. There were minor differences in individual 
dosing, since we selected patients who had already been using carvedilol or metoprolol 
depending on their own physician’s preferences. This might be a drawback of our study. The 
retrospective aspect of the study needs to be verified prospectively. The relatively well-
preserved renal function of the study population should also be considered when interpret-
ing the results. Renal function should be tested in patients with an elevated creatinine con-
centration who are particularly at risk of CIN and its complications. We excluded patients
who required percutaneous interventions; thus, a relatively low dose of radiocontrast agents 
was used. There were more patients using clopidogrel in the metoprolol group when compared 
to the carvedilol group. There is no clinical study that has examined the effect of clopidogrel 
on the development of CIN. In addition to its antiplatelet effect, clopidogrel also has anti-
inflammatory properties and improves endothelial function  [35] . High-maintenance doses 
(150 mg) of clopidogrel were also associated with a stronger improvement in endothelial 
function and a reduction of systemic inflammation compared with the standard dose (75 mg 
daily)  [35] . Thus, clopidogrel is probably not associated with susceptibility to CIN. Serum 
creatinine levels were measured immediately before and 48 h after contrast exposure. Evalu-
ating serum creatinine beyond the first 48 h would have revealed more patients with CIN.
 In conclusion, compared to metoprolol, carvedilol might protect against CIN develop-
ment by decreasing oxidative stress in patients undergoing coronary angiography. When a 
β-blocker therapy is indicated, carvedilol might be preferred to metoprolol in these patients.
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